EUCTR2006-004528-35-ES进行中（未招募）1 期
A multicentre, randomised, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 40 mg once daily versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer. -
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer. -Metastatic colorectal carcinomaMedDRA version: 8.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2006-004528-35-FRBoehringer Ingelheim France SAS90
进行中（未招募）
不适用
A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer. - Combination of BIBF 1120, BIBW 2992 and mFOLFOx7 as first-line therapy for colorectal cancerMetastatic colorectal carcinomaMedDRA version: 8.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2006-004528-35-DEBoehringer Ingelheim Pharma GmbH & Co. KG120
进行中（未招募）
1 期
A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - CORDELIABeta-thalassemia major (TM) or Diamond Blackfan anemia (DBA) or myelodysplastic syndromes (MDS) (low and INT-1 risk as per the IPSS for MDS) or sideroblastic anemia and myocardial iron overload as indicated by a T2* =6 but not greater than 20 ms, with no symptoms of cardiac dysfunction, and an MRI measured LVEF =56%.EUCTR2007-000766-20-GBovartis Pharma Services AG197
进行中（未招募）
不适用
A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions - NDMedDRA version: 9.1Level: LLTClassification code 10043388Term: ThalassaemiathalassemiaEUCTR2007-000766-20-ITOVARTIS FARMA192
招募中
1 期
Study evaluating AGuIX® nanopartcles in combinaison with radiotherapy for progressive / recurrent inoperable musculoskeletal tumor lesion.EUCTR2021-000571-37-FRCentre Léon Bérard132